Based on the Aerovate Therapeutics Inc stock forecast from 3 analysts, the average analyst target price for Aerovate Therapeutics Inc is USD 45.75 over the next 12 months. Aerovate Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Aerovate Therapeutics Inc is Bearish, which is based on 1 positive signals and 3 negative signals. At the last closing, Aerovate Therapeutics Inc’s stock price was USD 21.75. Aerovate Therapeutics Inc’s stock price has changed by +0.69% over the past week, -19.29% over the past month and +15.20% over the last year.
No recent analyst target price found for Aerovate Therapeutics Inc
No recent average analyst rating found for Aerovate Therapeutics Inc
Company Overview Aerovate Therapeutics Inc
N/A
N/A
N/A
N/A
USD
USA
Adjusted Closing Price for Aerovate Therapeutics Inc (AVTE)
Loading...
Unadjusted Closing Price for Aerovate Therapeutics Inc (AVTE)
Loading...
Share Trading Volume for Aerovate Therapeutics Inc Shares
Loading...
Compare Performance of Aerovate Therapeutics Inc Shares
Symbol
Capital Gain
Dividend Return
Total Return
Loading...
Loading...
Technical Indicators for AVTE
Assets
Top Holdings
N/A
Top Sectors
Top Regions
Stocks Similar To Aerovate Therapeutics Inc (Sector: Biotechnology )
Frequently Asked Questions About Aerovate Therapeutics Inc (AVTE) Stock
Based on ratings from 3 analysts Aerovate Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 3 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on AVTE's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for AVTE is USD 45.75 over the next 12 months. The maximum analyst target price is USD 65 while the minimum anlayst target price is USD 35.
AVTE stock's Price/Earning ratio is 0.88.
Our analysis grades AVTE stock's Price / Earning ratio at C-. This means that AVTE stock's Price/Earning ratio is above 28% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this AVTE may be undervalued for its sector.
The last closing price of AVTE's stock was USD 21.75.
The most recent market capitalization for AVTE is USD 0.60B.
Based on targets from 3 analysts, the average taret price for AVTE is projected at USD 45.75 over the next 12 months.
This means that AVTE's stock price may go up by +110.34% over the next 12 months.
We can't find any ETFs which contains Aerovate Therapeutics Inc's stock.
Sorry, we do not have any data on the number of employees for Aerovate Therapeutics Inc.
Sorry we do not have any infomation available on Aerovate Therapeutics Inc's address.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AVTE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
